ArticleEmerging microbes & infections2025
Grand Challenges on HIV/AIDS in China - The 5th Symposium, Yunnan 2024.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- [Impact of HIV-1 genotypes and population mobility on HIV-1 transmission in Guangzhou: a molecular transmission network analysis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Mortality trends and epidemiological characteristics among people living with HIV in Huangshi, China: a time-series analysis (2004-2024).BMC public health · 2026Article
- Geographical and temporal trends of HIV-1 subtypes and drug resistance in China: a nationwide study over two decades (2003-2024).The Journal of general virology · 2026Article
- Performance comparison of large language models for medication counseling in people living with HIV.Frontiers in public health · 2026Article
- Forecasting monthly AIDS incidence in China via LSTM-CNN parallel fusion: a comparative study of 10 predictive models.Frontiers in public health · 2026Article
- Cutting-edge developments in computer-aided anti-HIV drug design.Frontiers in immunology · 2026Review
- Molecular transmission network and drug resistance analysis of 404 HIV-1 cases infected through commercial heterosexual contact (2020-2024).Frontiers in public health · 2026Article
- Psychological resilience and social support as determinants of HIV-related stress in older adults living with HIV in China: a moderated mediation analysis.BMC public health · 2025Article
- Emergence ofMicroorganisms · 2025Article
- Factors associated with commercial sexual activities among students engaging in casual heterosexual behaviors: a cross-sectional study in Zhejiang Province.Frontiers in public health · 2025Article
- Rapid diagnosis of acute HIV-1 infection cases: first real-world performance of point-of-care HIV-1 nucleic acid testing in China.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV-1 infection has led to 1.329 million people living with the virus and 0.474 millions of deaths by the middle of 2024 in China. Achieving the goal of ending HIV/AIDS in China by 2030 has faced several grand challenges including currently having a diagnostic rate of less than 85%, an estimated annual cost burden of 6.3 billion RMB for antiretroviral therapy (ART) alone, and the lack of therapeutic cure and preventive vaccine and so on. To address these challenges, Chinese scientists initiated the programme of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.